Alexey Danilov, MD, PhD, discusses the current treatment landscape for chronic lymphocytic leukemia and how it has evolved.
Alexey Danilov, MD, PhD, associate director, Toni Stephenson Lymphoma Center, and professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, discusses the current treatment landscape for chronic lymphocytic leukemia (CLL) and how it has evolved.
With the addition of targeted therapies into the picture, patients with relapsed/refractory CLL have more options than ever before.
Patients can be treated with a number of options, including Bruton tyrosine kinase (BTK) inhibitors like ibrutinib (Imbruvica) and acalabrutinib (Calquence), PI3K inhibitors, B-cell lymphoma 2 inhibitors, venetoclax (Venclexta), and more.
Transcription:
0:08 | Over the last few years, we have seen a major paradigm shift in therapies for chronic lymphocytic leukemia. Now, introductions of novel targeted therapies such as the BCL-2 inhibitor, venetoclax, as well as BTK inhibitors, including ibrutinib and acalabrutinib in the treatment of CLL, have resulted in a significant reduction of use of chemoimmunotherapy regimens.
0:29 | Fludarabine-based therapies are still occasionally used in younger patients with mutated IGHV status. However, given the significant survival advantage of novel therapies, the use of this regimen has declined by a lot. Novel regimens result in significantly better safety profile as well.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More